Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis

被引:63
作者
Li, Jing [1 ]
Gao, Xu [2 ,3 ,4 ]
Luo, Tao [2 ,3 ,4 ]
Wu, Jie [1 ]
Sun, Gang [2 ,3 ,4 ]
Liu, Qingyun [2 ,3 ,4 ]
Jiang, Yuan [1 ]
Zhang, Yangyi [1 ]
Mei, Jian [1 ]
Gao, Qian [2 ,3 ,4 ]
机构
[1] Shanghai Municipal Ctr Dis Control & Prevent, Dept TB Control, Shanghai 200336, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Minist Educ, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China
[3] Fudan Univ, Inst Biomed Sci, Minist Hlth, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China
[4] Fudan Univ, Sch Basic Med Sci, Inst Med Microbiol, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
fluoroquinolones; MICs; M; tuberculosis; mutations; DNA GYRASE; CRYSTAL-STRUCTURE; SUSCEPTIBILITY; MOXIFLOXACIN; OFLOXACIN; DIAGNOSIS; REGION; DOMAIN; ASSAY;
D O I
10.1038/emi.2014.21
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate the association between mutations in the genes gyrA/B and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis, a total of 80 ofloxacin-resistant isolates collected in 2009 by the Shanghai Municipal Centers for Disease Control and Prevention were studied. The minimum inhibitory concentration (MIC) of ofloxacin, moxifloxacin and gatifloxacin for each isolate was determined using the microscopic observation drug susceptibility assay. Sequencing was used to identify mutations in the quinolone resistance-determining region (QRDR) of the gyrA and gyrB genes. In total, 68 isolates had mutations in gyrA, three isolates had mutations in gyrB, six isolates had mutations in both gyrA and gyrB, and three isolates had no mutations. Two common mutations in gyrA, the D94G and D94N mutations, were associated with higher-level resistance to all three fluoroquinolones than two other common mutations (A90V and D94A). Understanding the relationship between MICs and mutations in ofloxacin-resistant isolates will facilitate the optimization of the use of new-generation fluoroquinolones to treat patients with ofloxacin-resistant tuberculosis (TB).
引用
收藏
页数:5
相关论文
共 27 条
[1]   Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis [J].
Alffenaar, J. W. C. ;
van Altena, R. ;
Bokkerink, H. J. ;
Luijckx, G. J. ;
van Soolingen, D. ;
Aarnoutse, R. E. ;
van der Werf, T. S. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (07) :1080-1082
[2]  
[Anonymous], 2010, Multidrug and extensively drug-resistant TB(M/XDR-TB): 2010 Global Report on Surveillance and Response
[3]   Mycobacterium tuberculosis DNA gyrase:: Interaction with quinolones and correlation with antimycobacterial drug activity [J].
Aubry, A ;
Pan, XS ;
Fisher, LM ;
Jarlier, V ;
Cambau, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1281-1288
[4]   Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis:: Functional analysis of mutant enzymes [J].
Aubry, A ;
Veziris, N ;
Cambau, E ;
Truffot-Pernot, C ;
Jarlier, V ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :104-112
[5]  
Barrera L., 2008, Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs
[6]   Crystal structure of the breakage-reunion domain of DNA gyrase [J].
Cabral, JHM ;
Jackson, AP ;
Smith, CV ;
Shikotra, N ;
Maxwell, A ;
Liddington, RC .
NATURE, 1997, 388 (6645) :903-906
[7]   Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009 [J].
Cui, Zhenling ;
Wang, Jie ;
Lu, Junmei ;
Huang, Xiaochen ;
Hu, Zhongyi .
BMC INFECTIOUS DISEASES, 2011, 11
[8]  
Da SPE, 2011, FEMS IMMUNOL MED MIC, V63, P1
[9]   Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance [J].
Devasia, Rose A. ;
Blackman, Amondrea ;
May, Carolyn ;
Eden, Svetlana ;
Smith, Teresa ;
Hooper, Nancy ;
Maruri, Fernanda ;
Stratton, Charles ;
Shintani, Ayumi ;
Sterling, Timothy R. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) :1173-1178
[10]   WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update [J].
Falzon, D. ;
Jaramillo, E. ;
Schuenemann, H. J. ;
Arentz, M. ;
Bauer, M. ;
Bayona, J. ;
Blanc, L. ;
Caminero, J. A. ;
Daley, C. L. ;
Duncombe, C. ;
Fitzpatrick, C. ;
Gebhard, A. ;
Getahun, H. ;
Henkens, M. ;
Holtz, T. H. ;
Keravec, J. ;
Keshavjee, S. ;
Khan, A. J. ;
Kulier, R. ;
Leimane, V. ;
Lienhardt, C. ;
Lu, C. ;
Mariandyshev, A. ;
Migliori, G. B. ;
Mirzayev, F. ;
Mitnick, C. D. ;
Nunn, P. ;
Nwagboniwe, G. ;
Oxlade, O. ;
Palmero, D. ;
Pavlinac, P. ;
Quelapio, M. I. ;
Raviglione, M. C. ;
Rich, M. L. ;
Royce, S. ;
Ruesch-Gerdes, S. ;
Salakaia, A. ;
Sarin, R. ;
Sculier, D. ;
Varaine, F. ;
Vitoria, M. ;
Walson, J. L. ;
Wares, F. ;
Weyer, K. ;
White, R. A. ;
Zignol, M. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (03) :516-528